Platform Technologies and the Collaboration Paradox
Executive Summary
For all the innovations they promise in a drug industry with me-too products, the fact remains that contemporary drug discovery technologies increase the time required to produce a new drug. In genomics, companies now pursue their own targets, looking to create as much intellectual property around them as possible. They thereby keep their competitors away from the field--but they also lose their help.
You may also be interested in...
Stockwatch: Reading The Tea Leaves For Pharma Q1 Earnings
Contrasting first-quarter preannouncements from a DNA sequencing company and a molecular diagnostics company may, with other seasonal pressures, imply a comparatively weak first quarter for therapeutic drug companies.
EU Medtech May Have Standards Certainty Days Before MDR Applies
The EU’s Medical Device Regulation applies in just over a month’s time and the IVD Regulation in just over a year. But the standards underpinning them are way behind. Will they get the green light at last
Gilead Keeps Close Eye On Stormy Remdesivir Situation In India
Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.